This is a crucial step in order to make gene therapy more effective and to increase the number of patients able to access it.

In the study, the firm will enroll previously treated patients whose tumors are positive for FRα based on IHC testing.

Company Expects to Announce VAX-31 Infant Study Topline Safety, Tolerability and Immunogenicity Data from Primary ...

Epsilogen, the global leader in the development of immunoglobulin E (IgE) antibodies to treat cancer, today announces that it has commenced a Phase Ib study evaluating MOv18 IgE in patients with ...

Namilumab failed to show treatment benefit in patients with pulmonary sarcoidosisFurther development of namilumab for the treatment of ...

Multiplexed assays of variant effect are an increasingly important tool in genetic research and including more context specificity in their design would aid interpretation and discovery.